Correlation Between Emergent Biosolutions and Checkpoint Therapeutics

Can any of the company-specific risk be diversified away by investing in both Emergent Biosolutions and Checkpoint Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Emergent Biosolutions and Checkpoint Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Emergent Biosolutions and Checkpoint Therapeutics, you can compare the effects of market volatilities on Emergent Biosolutions and Checkpoint Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Emergent Biosolutions with a short position of Checkpoint Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Emergent Biosolutions and Checkpoint Therapeutics.

Diversification Opportunities for Emergent Biosolutions and Checkpoint Therapeutics

-0.41

Correlation Coefficient

Emergent Biosolutions  Checkpoint Therapeutics

Very good diversification

The 3 months correlation between Emergent and Checkpoint is -0.41. Overlapping area represents the amount of risk that can be diversified away by holding Emergent Biosolutions and Checkpoint Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Checkpoint Therapeutics and Emergent Biosolutions is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Emergent Biosolutions are associated (or correlated) with Checkpoint Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Checkpoint Therapeutics has no effect on the direction of Emergent Biosolutions i.e., Emergent Biosolutions and Checkpoint Therapeutics go up and down completely randomly.

Pair Corralation between Emergent Biosolutions and Checkpoint Therapeutics

Considering the 90-day investment horizon Emergent Biosolutions is expected to under-perform the Checkpoint Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Emergent Biosolutions is 2.02 times less risky than Checkpoint Therapeutics. The stock trades about -0.23 of its potential returns per unit of risk. The Checkpoint Therapeutics is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  335.00  in Checkpoint Therapeutics on December 30, 2024 and sell it today you would earn a total of  69.00  from holding Checkpoint Therapeutics or generate 20.6% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Emergent Biosolutions  vs.  Checkpoint Therapeutics

Emergent Biosolutions

Risk-Adjusted Performance

Very Weak

Over the last 90 days Emergent Biosolutions has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Checkpoint Therapeutics

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Checkpoint Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Checkpoint Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Emergent Biosolutions and Checkpoint Therapeutics

The main advantage of trading using opposite Emergent Biosolutions and Checkpoint Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Emergent Biosolutions position performs unexpectedly, Checkpoint Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Checkpoint Therapeutics will offset losses from the drop in Checkpoint Therapeutics' long position.

The idea behind Emergent Biosolutions and Checkpoint Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.